Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M. +2 more·2001·New England Journal of Medicine
DOI 10.1056/nejmoa011161

Cited by (7,499)

Items 901–1,000 of 7,499

  1. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition
    Hélène François, Sandrine Placier, Martin Flamant, Pierre‐Louis Tharaux, Dominique Chansel, Jean‐Claude Dussaule, Christos Chatziantoniou · 2004 · The FASEB Journal
  2. Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
    Catalá-López, Ferrán, Macías Saint-Gerons, Diego, González-Bermejo, Diana, Rosano, Giuseppe M., Davis, Barry R., Ridao, Manuel, Zaragoza, Abel, Montero-Corominas, Dolores, Tobías, Aurelio, de la Fuente-Honrubia, César et al. · 2016 · PLOS Medicine
  3. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes
    Cooper, Mark E., Perkovic, Vlado, McGill, Janet B., Groop, Per-Henrik, Wanner, Christoph, Rosenstock, Julio, Hehnke, Uwe, Woerle, Hans-Juergen, von Eynatten, Maximilian · 2015 · American Journal of Kidney Diseases
  4. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
    The EMPA-KIDNEY Collaborative Group, Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen et al. · 2022 · Nephrology Dialysis Transplantation
  5. Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
    Richard E. Gilbert · 2013 · Kidney International
  6. Association between renin–angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study
    Magnus Edner, Lina Benson, Ulf Dahlström, Lars H. Lund · 2015 · European Heart Journal
  7. Diabetes, Inflammation, Proinflammatory Cytokines, and Diabetic Nephropathy
    Juan F. Navarro‐González, Carmen Mora Fernández · 2006 · The Scientific World JOURNAL
  8. Urinary Connective Tissue Growth Factor Excretion in Patients With Type 1 Diabetes and Nephropathy
    Richard E. Gilbert, Aysel Akdeniz, Stephen Weitz, William R. Usinger, Christopher J. Molineaux, Susan Jones, Robyn G. Langham, George Jerums · 2003 · Diabetes Care
  9. Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
    James R. Sowers, Steven M. Haffner · 2002 · Hypertension
  10. An Endocrinologist-Supported Intervention Aimed at Providers Improves Diabetes Management in a Primary Care Site
    Phillips, Lawrence S., Ziemer, David C., Doyle, Joyce P., Barnes, Catherine S., Kolm, Paul, Branch, William T., Caudle, Jane M., Cook, Curtiss B., Dunbar, Virginia G., El-Kebbi, Imad M. et al. · 2005 · Diabetes Care
  11. Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results
    Remuzzi, Giuseppe, Ruggenenti, Piero, Perna, Annalisa, Dimitrov, Borislav D., de Zeeuw, Dick, Hille, Darcy A., Shahinfar, Shahnaz, Carides, George W., Brenner, Barry M. · 2004 · Journal of the American Society of Nephrology
  12. Novel Therapies for Diabetic Kidney Disease
    Radica Z. Alicic, Katherine R. Tuttle · 2014 · Advances in Chronic Kidney Disease
  13. The expanding spectrum of biological actions of vitamin D
    Jorge Enrique Rojas-Rivera, Concepción de la Piedra, Ana Ramos, Alberto Ortíz, Jesús Egido · 2010 · Nephrology Dialysis Transplantation
  14. Acute kidney injury is a risk factor for subsequent proteinuria
    Sharidan K. Parr, Michael Edwin Matheny, Khaled F. M. Abdel-Kader, Robert A. Greevy, Aihua Bian, James Fly, Guanhua Chen, Theodore Speroff, Adriana M. Hung, Talat Alp Ikizler et al. · 2017 · Kidney International
  15. Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases
    Weihuang Zhang, Xiaoyu Li, Shujun Wang, Yanse Chen, Huafeng Liu · 2020 · Cell Death Discovery
  16. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study
    Christian Razo, Catherine A. Welgan, Catherine Owens Johnson, Susan A. McLaughlin, Vincent C Iannucci, Anthony Rodgers, Nelson Wang, Kate E LeGrand, Reed J D Sorensen, Jiawei He et al. · 2022 · Nature Medicine
  17. Recent hypertension trials
    Bryan Williams · 2005 · Journal of the American College of Cardiology
  18. Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies
    Albert A. Carr, Peter Russell Kowey, Richard B. Devereux, Barry Morton Brenner, Björn Dahlöf, Hans Ibsen, Lars Hjalmar Lindholm, Paulette A. Lyle, Steven M. Snapinn, Zhongxin Zhang et al. · 2005 · The American Journal of Cardiology
  19. The Cardiorenal Syndrome in Heart Failure
    Kevin Damman, Adriaan A. Voors, Gerjan J Navis, Dirk Jan van Veldhuisen, Hans L. Hillege · 2011 · Progress in Cardiovascular Diseases
  20. Chronic Angiotensin II Receptor Blockade Reduces (Intra)Renal Vascular Resistance in Patients with Type 2 Diabetes
    Danilo Fliser, Kathrin-Kristin Wagner, Astrid Loos · 2005 · Journal of the American Society of Nephrology
  21. Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study
    Gerald B. Appel, Jai Radhakrishnan, Morrell M. Avram, Ralph A. DeFronzo, F. Escobar‐Jiménez, M.M. Campos, Ellen D. Burgess, Darcy A. Hille, Tania Z. Dickson, Shahnaz Shahinfar et al. · 2003 · Diabetes Care
  22. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
  23. Diets For Patients With Chronic Kidney Disease, Still Worth Prescribing
    William E. Mitch, Giuseppe Remuzzi · 2004 · Journal of the American Society of Nephrology
  24. Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
    Shivangi Dwivedi, Mukesh Singh Sikarwar · 2024 · Hormone and Metabolic Research
  25. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target?
    Athanase D. Protogerou, Theodore G. Papaioannou, Jacques Blacher, Christos M. Papamichael, John P Lekakis, Michel E. Safar · 2007 · Journal of Hypertension
  26. Therapeutic strategies to slow chronic kidney disease progression
    Elke Wühl, Franz S. Schaefer · 2008 · Pediatric Nephrology
  27. Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management
    Günter Wolf, Eberhard Ritz · 2003 · Journal of the American Society of Nephrology
  28. Intensive Integrated Therapy of Type 2 Diabetes
    Gæde, Peter, Pedersen, Oluf · 2004 · Diabetes
  29. Day-to-day variability in spot urine albumin-creatinine ratio
    Naresh, Chetana N., Hayen, Andrew, Weening, Alexander, Craig, Jonathan C., Chadban, Steven J. · 2013 · American Journal of Kidney Diseases
  30. Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States
    Murphy, Daniel P., Drawz, Paul E., Foley, Robert N. · 2019 · Journal of the American Society of Nephrology
  31. Diabetic nephropathy: landmark clinical trials and tribulations
    Gary C.W. Chan, Sydney C.W. Tang · 2015 · Nephrology Dialysis Transplantation
  32. New pharmacological strategies for protecting kidney function in type 2 diabetes
    Marcel H.A. Muskiet, David Collins. Wheeler, Hiddo J.L. Heerspink · 2018 · The Lancet Diabetes & Endocrinology
  33. Comprehensive approach to diabetic nephropathy
    Bancha Satirapoj, Sharon G. Adler · 2014 · Kidney Research and Clinical Practice
  34. Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus
    Hiroki Yokoyama, Naoto Katakami, Yoshimitsu Yamasaki · 2006 · Stroke
  35. Diabetic Nephropathy
    American Diabetes Association · 2002 · Diabetes Care
  36. Omega-3 Polyunsaturated Fatty Acids in the Treatment of Kidney Disease
    Robert Gordon Fassett, Glenda Carolyn Gobe, Jonathan M. Peake, Jeff Scott Coombes · 2010 · American Journal of Kidney Diseases
  37. Population-Wide Screening for Chronic Kidney Disease
    Marika Mae Cusick, Rebecca Lauren Tisdale, Glenn Matthew Chertow, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert · 2023 · Annals of Internal Medicine
  38. Diabetic Nephropathy: The Proteinuria Hypothesis
    Mark E. Williams · 2005 · American Journal of Nephrology
  39. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    Hermann G. Haller, Gian Carlo Viberti, Albert Mimran, Giuseppe Remuzzi, Ton J. Rabelink, Eberhard Ritz, Lars Christian Rump, Luis Miguel Ruilope, Shigehiro Katayama, Sadayoshi Ito et al. · 2006 · Journal of Hypertension
  40. Olmesartan Medoxomil
    Lesley J. Scott, Paul L. McCormack · 2008 · Drugs
  41. Access to health care among status Aboriginal people with chronic kidney disease
    S. Gao, Braden Manns, Bruce F. Culleton et al. · 2008 · Canadian Medical Association Journal
  42. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy
    M. Satoh, S. Fujimoto, S. Arakawa, Toyotaka Yada, Tamehachi Namikoshi, Yoshisuke Haruna, H. Horike, Tamaki Sasaki, Naoki Kashihara · 2008 · Nephrology Dialysis Transplantation
  43. Neprilysin inhibition in chronic kidney disease
    P. Judge, Richard Haynes, Martin Landray, Colin Baigent · 2014 · Nephrology Dialysis Transplantation
  44. The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease
    Gavin Dreyer, Sally Hull, Zoe Aitken · 2009 · QJM
  45. Historical Trends and Milestones in Hypertension Research
    Theodore A. Kotchen · 2011 · Hypertension
  46. Diabetes and Metabolism
    Alicia Juliana Kowaltowski, Fernando Abdulkader · 2020 · Springer eBooks
  47. Hypertension and diabetes
    Karin Agnes Maria Jandeleit-Dahm, Mark Emmanuel Cooper · 2002 · Current Opinion in Nephrology & Hypertension
  48. Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy
    Masanori Abe, Noriaki Maruyama, Kazuyoshi Okada, Shiro Matsumoto, Koichí Matsumoto, Masayoshi Soma · 2011 · Journal of Atherosclerosis and Thrombosis
  49. Chronic Kidney Disease in Diabetes
    Philip A. McFarlane, David Z.I. Cherney, Richard E. Gilbert, Peter Alexander Senior · 2018 · Canadian Journal of Diabetes
  50. Hypertension and the kidneys
    Aine Maire De Bhailis, Philip A. Kalra · 2022 · British Journal of Hospital Medicine
  51. Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension
    Benjamin J Epstein, Katherine Vogel, Biff F. Palmer · 2007 · Drugs
  52. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?
    Matthew Fomonyuy Yuyun, Amanda Adler, Nicholas J. Wareham · 2005 · Current Opinion in Nephrology & Hypertension
  53. A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE
    Gianluigi Savarese, Pierluigi Costanzo, John G.F. Cleland, Enrico Vassallo, Donatella Ruggiero, Giuseppe M.C. Rosano, Pasquale Perrone Filardi · 2013 · Rational Pharmacotherapy in Cardiology
  54. Effects of Brazilian green propolis on proteinuria and renal function in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled trial
    Marcelo Augusto Duarte Silveira, Flávio Teles, A. Berretta, Talita Rojas Sanches, Camila Eleutério Rodrigues, Antônio Carlos Seguro, Lúcia Andrade · 2019 · BMC Nephrology
  55. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function
    Mathilda Bedin, Olivia Boyer, Aude Servais, Yong Li, Laure Villoing-Gaudé, Marie-Josèphe Tête, Alexandra Cambier, Julien Hogan, Véronique Baudouin, Saoussen Krid et al. · 2019 · Journal of Clinical Investigation
  56. eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
    Alejandro Meraz-Muñoz, Jordan J. Weinstein, Ron Wald · 2021 · Kidney360
  57. Key metalloproteinase-mediated pathways in the kidney
    Justyna Wozniak, Jürgen Floege, Tammo Ostendorf · 2021 · Nature Reviews Nephrology
  58. Up-Date on Diabetic Nephropathy
    Maria Chiara Pelle, Michele Provenzano, Marco Busutti, Clara Valentina Porcu, Isabella Zaffina, Lucia Stanga, Franco Arturi · 2022 · Life
  59. Angiotensin II AT2 receptor subtype
    Massimo Volpe, Beatrice Musumeci, Paola De Paolis · 2003 · Journal of Hypertension
  60. Integrating albuminuria and GFR in the assessment of diabetic nephropathy
    George Jerums, Sianna Panagiotopoulos, Erosha Premaratne, Richard J. MacIsaac · 2009 · Nature Reviews Nephrology
  61. Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering
    Vlado Perkovic, Toshiharu Ninomiya, Hisatomi Arima, Martin Gallagher, Meg Jardine, Alan Cass, Bruce Charles Neal, Stephen W MacMahon, John Philip Chalmers · 2007 · Journal of the American Society of Nephrology
  62. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation
    Luis Celso Matavelli, Jiqian Huang, Helmy M. Siragy · 2009 · Clinical and Experimental Pharmacology and Physiology
  63. New insights into angiotensin receptor actions: from blood pressure to aging
    Johannes Stegbauer, Thomas M. Coffman · 2010 · Current Opinion in Nephrology & Hypertension
  64. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
    Matthew R. Weir, Jay Ian Lakkis, Bernard G. Jaar, Michael V. Rocco, Michael Jin Choi, Holly Kramer, Elaine Ku · 2018 · American Journal of Kidney Diseases
  65. Mechanisms of Disease: local renin–angiotensin–aldosterone systems and the pathogenesis and treatment of cardiovascular disease
    Richard N. Ré · 2004 · Nature Clinical Practice Cardiovascular Medicine
  66. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure
    Radko Komers, T Oyama, Douglas R. Beard, Chris Tikellis, Bei Xu, Daniel F. Lotspeich, Sharon Anderson · 2010 · Kidney International
  67. Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus
    Piero Luigi Ruggenenti, Giuseppe Lauria, Ilian Petrov Iliev, Anna Fassi, Aneliya Ilieva Parvanova, Stefano Rota, Carlos R. Chiurchiu, Draženka Pongrac Barlovič, Angelo Sghirlanzoni, Raffaella Lombardi et al. · 2011 · Hypertension
  68. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004
    Suh, Dong-Churl, Kim, Chul-Min, Choi, In-Sun, Plauschinat, Craig A, Barone, Joseph A · 2009 · Journal of Hypertension
  69. Angiotensin II- and Salt-Induced Kidney Injury through Rac1-Mediated Mineralocorticoid Receptor Activation
    Wakako Kawarazaki, Miki Nagase, Shigetaka Yoshida, Maki Takeuchi, Kenichi Ishizawa, Nobuhiro Ayuzawa, Kohei Ueda, Toshiro Fujita · 2012 · Journal of the American Society of Nephrology
  70. Low-grade albuminuria and cardiovascular risk
    Roland Erich Schmieder, Joachim Schrader, Walter Zidek, Ulrich Tebbe, W. Dieter Paar, Peter Bramlage, D Pittrow, Michael Böhm · 2007 · Clinical Research in Cardiology
  71. Chronic kidney disease and diabetes.
    Ronald Pyram, Abhishek Kansara, M. Banerji, Lisel Loney-Hutchinson · 2012 · Maturitas
  72. Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction
    Harvey Douglas White, Philip E. Aylward, Zhen Huang, Anthony J. Dalby, W. Douglas Weaver, Ståle Barvik, José Antônio Marin‐Neto, Ján Murín, Rolf Nordlander, Wiek H. van Gilst et al. · 2005 · Circulation
  73. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats
    Yuichi Kikuchi, Muneharu Yamada, Toshihiko Imakiire, Taketoshi Kushiyama, Keishi Higashi, Naomi Hyodo, Kojiro Yamamoto, Oda T, Shigenobu Suzuki, Soichiro Miura · 2007 · Journal of Endocrinology
  74. Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy
    Sofia Bano Ahmed, Peter Hambak Hovind, Hans‐Henrik Parving, Peter R Rossing, Deborah A. Price, Lori M. Laffel, Maria Cecilia Lansang, Radomir D Stevanovic, Naomi D.L. Fisher, Norman K. Hollenberg · 2005 · Diabetes Care
  75. THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Traditional Cardiac Risk Factors in Individuals with Chronic Kidney Disease
    Katrin Uhlig, Andrew S. Levey, Mark J. Sarnak · 2003 · Seminars in Dialysis
  76. Chronic Kidney Disease in Diabetes
    Philip A. McFarlane, Richard E. Gilbert, Lori MacCallum, Peter Alexander Senior · 2013 · Canadian Journal of Diabetes
  77. Prevalence of Chronic Kidney Disease and Survival among Aboriginal People
    Song Gao, Braden Manns, Bruce F. Culleton · 2007 · Journal of the American Society of Nephrology
  78. Inhibition of SET Domain–Containing Lysine Methyltransferase 7/9 Ameliorates Renal Fibrosis
    Kensuke Sasaki, Shigehiro Doi, Ayumu Nakashima, Taisuke Irifuku, Kyoko Yamada, Keiko Kokoroishi, Toshinori Ueno, Toshiki Doi, Eisuke Hida, Koji Arihiro et al. · 2015 · Journal of the American Society of Nephrology
  79. Effects of blood-pressure-lowering treatment in hypertension
    Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti · 2016 · Journal of Hypertension
  80. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease
    Claudia Pontillo, Harald Mischak · 2017 · Clinical Kidney Journal
  81. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
    Maria Eleni Alexandrou, Aikaterini A. Papagianni, Απόστολος Τσάπας, Charalampos Loutradis, Afroditi Boutou, Alexia Piperidou, Dorothea Papadopoulou, Luis Miguel Ruilope, George L. Bakris, Pantelis A. Sarafidis · 2019 · Journal of Hypertension
  82. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
    Björn Pasternak, Viktor Wintzell, Mads Melbye, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Henrik Svanström et al. · 2020 · BMJ
  83. Renin–Angiotensin System Blockade and Cardiovascular and Renal Protection
    Byron J. Hoogwerf · 2009 · The American Journal of Cardiology
  84. An extremely high dose of losartan affords superior renoprotection in the remnant model
    Clarice Kazue Fujihara, Mariliza Velho Rodrigues, Denise Maria Avancini Costa Malheiros, Roberto Zatz · 2005 · Kidney International
  85. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET
    Th. Philipp, Frank Martinez, Helmut Geiger, Bruno Moulin, Georges Mourad, Roland Erich Schmieder, Michel M Lièvre, Uwe W. Heemann, Ch. Legendre · 2009 · Nephrology Dialysis Transplantation
  86. Progression of Renal Disease
    Karen A. Griffin, ANIL K. BIDANI · 2006 · Clinical Journal of the American Society of Nephrology
  87. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
    Strippoli, Giovanni FM, Bonifati, Carmen, Craig, Maria E, Navaneethan, Sankar D, Craig, Jonathan C · 2006 · Cochrane Database of Systematic Reviews
  88. Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety
    Addison A. Taylor, Helmy M. Siragy, Shawna D. Nesbitt · 2011 · Journal of Clinical Hypertension
  89. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects
    Carla Zoja, Daniela Corna, Valeria Nava, Monica Locatelli, Mauro Abbate, Flavio Gaspari, Fabiola Carrara, Fabio Sangalli, Giuseppe Remuzzi, Ariela Benigni · 2012 · American Journal of Physiology-Renal Physiology
  90. Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
    Ian H. de Boer, Maryam Afkarian, Tessa C. Rue, Patricia A. Cleary, John M. Lachin, Mark E. Molitch, Michael W. Steffes, Wanjie Sun, Bernard Zinman · 2014 · Journal of the American Society of Nephrology
  91. Fibrosis: cross-organ biology and pathways to development of innovative drugs
    Florian Rieder, Laura E. Nagy, Toby M. Maher, Jörg H. W. Distler, Rafael Kramann, Boris Hinz, Marco Prunotto · 2025 · Nature Reviews Drug Discovery
  92. Diabetic Nephropathy
    Katalin Suszták, Erwin P. Böttinger · 2006 · Journal of the American Society of Nephrology
  93. Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?
    Roberto Pecoits‐Filho, Peter Stenvinkel, Angela Yee-Moon Wang, Olof Heimbürger, Bengt Lindholm · 2004 · Peritoneal Dialysis International
  94. Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes
    Braden Manns, Marcello A. Tonelli, Jianguo Zhang, David J.T. Campbell, Peter M. Sargious, Bharati Ayyalasomayajula, Fiona M Clement, Jeffrey A. Johnson, Andreas Laupacis, Richard Z Lewanczuk et al. · 2011 · Canadian Medical Association Journal
  95. Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
    N.H. Andersen, Per Loegstrup Poulsen, Søren Tang Knudsen, Steen Hvitfeldt Poulsen, Hans Eiskjær, Klavs Würgler Hansen, Kjeld Helleberg, Carl Erik Mogensen · 2005 · Diabetes Care
  96. Complement activation in patients with diabetic nephropathy
    X.-Q. Li, Dong‐Yuan Chang, M. Chen, Ming‐Hui Zhao · 2018 · Diabetes & Metabolism
  97. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis
    Kanran Wang, Jinbo Hu, Ting Luo, Yue Wang, Shumin Yang, 青华, Qingfeng Cheng, Qifu Li · 2018 · Kidney & Blood Pressure Research
  98. microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney
    Swayam Prakash Srivastava, Ahmad F. Hedayat, Keizo Kanasaki, Julie E. Goodwin · 2019 · Frontiers in Pharmacology
  99. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
    Tamara Isakova, Orlando M. Gutiérrez, Myles Selig Wolf · 2009 · Kidney International
  100. Effect of Microalbuminuria Lowering on Regression of Left Ventricular Hypertrophy in Children and Adolescents with Essential Hypertension
    Farahnak K. Assadi · 2007 · Pediatric Cardiology